NewBridge Pharmaceuticals, a specialty therapeutics company focused on pharmaceuticals,s, biologics, diagnostics and medical devices serving the AfMET markets (Africa, Middle East, Turkey and Caspian regions), today announced that it has entered into an exclusive agreement with Genomic Health, Inc. (NASDAQ: GHDX), a global health company that provides actionable genomic information to personalize genomic health decisions.
Through this agreement, Genomic Health Inc. will provide NewBridge Pharmaceuticals with Oncotype DX® test that can help physicians use their patients’ tumor biology to go beyond the traditional clinical and pathologic factors to establish a more appropriate treatment plan for an individual patient.” As part of this agreement, NewBridge will offer the Oncotype DX® tests for treatment of patients with early-stage, estrogen-positive (ER+) invasive breast cancer, ductal carcinoma in situ of the breast (DCIS), as well as colon cancer patients at stage II and III.
The multi-gene Oncotype DX® test has been shown to predict the risk of recurrence and likelihood of chemotherapy benefit in invasive breast cancer. It also forecasts the possibility of recurrence in pre-invasive breast cancer or ductal carcinoma in situ. The test can help patients and their doctors determine the most likely progression of the disease in order to make more informed decisions about their individual treatment. Multiple studies from different countries have shown that the knowledge of the Oncotype DX® test’s Recurrence Score® result changes physician treatment recommendations in about 30 percent of their early-stage, ER+ invasive breast cancer patients.
Joe Henein, President and Chief Executive Officer, NewBridge Pharmaceuticals, said: “Breast cancer is the most common cancer in Arab women, constituting up to 42 percent of all cancers in women, and presents itself almost 10 years earlier in comparison to women affected by breast cancer in the US and Europe.”
He added: “While facing a difficult decision about chemotherapy treatment, the Oncotype DX® test can help women with ER+, node negative or DCIS breast cancer make the treatment decision that is right for them. In addition, as colon cancer rates are also high in the region, we are pleased to provide Oncotype DX® Colon Cancer, a diagnostic test that can help determine the likelihood of colon cancer returning after surgery in patients who are considering chemotherapy.”
The Oncotype DX® colon cancer test is a clinically validated multi-gene test that can help men and women with stage II and stage III colon cancer learn more about the biological features of their specific tumor by indicating the likelihood that a patient’s cancer may return in the future. Coupled with other pieces of information, the results from the Oncotype DX®test can help patients and their doctors make personalized decisions about whether or not to include chemotherapy in their treatment plan.
“Licensing Genomic Health’s innovative molecular tests underpins our long-term strategic mission to bridge the access gap and bring new technologies into the AfMET region to serve the unmet medical needs of our patients,” said Joe Henein. “A genomic test such as Oncotype DX® has an important role to play in improving treatment decision making and ultimately impacting on quality of care.”
Source: Zawya.Com – Press release – 4 September 2012